<SEC-DOCUMENT>0001193125-19-133212.txt : 20190620
<SEC-HEADER>0001193125-19-133212.hdr.sgml : 20190620
<ACCEPTANCE-DATETIME>20190501165055
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-19-133212
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20190501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IDEAYA Biosciences, Inc.
		CENTRAL INDEX KEY:			0001676725
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474268251
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		7000 SHORELINE COURT, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-443-6209

	MAIL ADDRESS:	
		STREET 1:		7000 SHORELINE COURT, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ideaya Biosciences, Inc.
		DATE OF NAME CHANGE:	20160609
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter.</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g637842g40k53.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g637842g31m72.jpg" ALT="LOGO">
</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FOIA
Confidential Treatment Request</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Under 17 C.F.R. &#167;200.83</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;1, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Via
EDGAR and Overnight Delivery</U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, DC 20549-1090 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;Liz
Walsh, Staff Attorney </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Chris Edwards, Staff Attorney </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Jorge Bonilla, Staff Accountant </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mark Rakip, Staff Accountant </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Re:&nbsp;&nbsp;&nbsp;&nbsp;IDEAYA Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Filed on April&nbsp;26, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>File <FONT STYLE="white-space:nowrap">No.&nbsp;333-231081</FONT> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of IDEAYA
Biosciences, Inc. (the &#147;<B><I>Company</I></B>&#148;), set forth below is information in response to comment number 9 contained in the letter to the Company dated February&nbsp;15, 2019 from the staff (the &#147;<B><I>Staff</I></B>&#148;) of the
Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) relating to the Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> that was originally confidentially submitted to the Commission on
January&nbsp;17, 2019 and, as subsequently revised, was publicly filed by the Company on April&nbsp;26, 2019 (the &#147;<B><I>Registration Statement</I></B>&#148;). The supplemental response set forth below is based upon information provided to
Latham&nbsp;&amp; Watkins LLP by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of the Company, we are respectfully requesting confidential treatment for
specified portions of this letter pursuant to Rule 83 promulgated by the Commission, 17 C.F.R. &#167;200.83. This letter is accompanied by such request for confidential treatment because of the commercially sensitive nature of the information
discussed in this letter. A redacted version of this letter will be filed with the Commission on EDGAR, omitting the confidential information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-1001</B></P></TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>May 1, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Page 2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g637842g74y57.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company confirms to the Staff
that no price range has yet been provided in the preliminary prospectus included in the Registration Statement. However, the Company has authorized us to inform the Staff supplementally that, based on consultations with the lead underwriters, input
received from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">testing-the-waters</FONT></FONT> meetings (the &#147;<B><I>TTW Meetings</I></B>&#148;), and considerations of the current market conditions, if the marketing of the
initial public offering (the &#147;<B><I>IPO</I></B>&#148;) were to commence today, the Company&#146;s present view is that the estimated offering range would be $[***] to $[***] per share (the &#147;<B><I>Preliminary IPO Price Range</I></B>&#148;).
The share numbers, Preliminary IPO Price Range, exercise prices and fair values do not take into account a reverse stock split that the Company intends to implement in connection with the IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company advises the Staff that the Preliminary IPO Price Range represents the Company&#146;s current belief of what the indicative price
range in the preliminary prospectus may be, but that the actual indicative price range in the preliminary prospectus will not be determined until the Company completes a valuation process with the underwriters of the IPO, which is expected to occur
shortly before the printing of the preliminary prospectus for the IPO. Therefore, the preliminary estimated indicative price range is subject to further change as a result of various factors, including market conditions and subsequent developments
with respect to the Company&#146;s business. Upon completion of this valuation process, the Company will narrow the indicative price range to establish a bona fide offering price range not to be greater than $[***] between the low end of the range
and the top end of the range. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To assist the Staff in its evaluation of the Company&#146;s stock-based compensation, the Company has
provided the analysis as set forth below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GRANTS OF COMMON STOCK OPTIONS DURING THE PRECEDING 15 MONTHS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes by month of grant date the number of shares of common stock underlying stock options granted during the previous
fifteen months, as well as the associated per share exercise price and the estimated fair value per share of the Company&#146;s common stock on the grant date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Underlying<BR>Stock&nbsp;Options<BR>Granted</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair&nbsp;Value&nbsp;per&nbsp;Share</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>March&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>April&nbsp;13, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>April&nbsp;30, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>June&nbsp;20, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>June&nbsp;30, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>July&nbsp;28, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>July&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>August&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>October&nbsp;3, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;11, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>January&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>March&nbsp;13, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>March&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>$[***]</B></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>[***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-1002</B></P></TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>May 1, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Page 3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g637842g74y57.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Valuation Date (As of)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fair Value Per Share of Common Stock</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>January&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>$[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>May&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>$[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>November&nbsp;30, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>$[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>February&nbsp;28, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>$[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>DETERMINATION OF FAIR VALUE OF COMMON STOCK </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the Registration Statement, the Company has historically determined the fair value of its common stock using methodologies,
approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation </I>(the &#147;<B><I>Practice
Guide</I></B>&#148;). Specifically, the fair value of the shares of common stock underlying the Company&#146;s stock options has been determined by the Company&#146;s Board of Directors (the &#147;<B><I>Board</I></B>&#148;). Because there has been
no public market for the Company&#146;s common stock, and in the absence of recent <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> cash sales transactions of the Company&#146;s common stock with independent third parties, the Board has
determined the fair value of the common stock by considering, at the time of grant, a number of objective and subjective factors, including independent third-party valuations as of January&nbsp;31, 2018, May&nbsp;31, 2018, November&nbsp;31, 2018,
and February&nbsp;28, 2019. The Board gave consideration to expected material grants of common stock options in determining when to obtain independent third-party valuations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These independent third-party valuations have utilized a hybrid approach of the option pricing method (<B><I>&#147;OPM&#148;</I></B>) and the
probability-weighted expected return method (<B><I>&#147;PWERM&#148;</I></B>), an accepted valuation approach under the Practice Guide, for determining the fair value of the Company&#146;s common stock. The hybrid method is performed by first
estimating the probability-weighted value across multiple scenarios and then using the OPM to estimate the allocation of value within one or more of those scenarios. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The OPM relies on financial option theory to allocate value among different classes of members&#146; equity based upon a future option
&#147;claim&#148; on value. Under the OPM, the values of the various classes of stock are estimated as the net value of a series of call options, representing the present value of the expected future returns to the shareholders. The OPM may be used
to determine the equity value of a company by using the OPM backsolve method. In an OPM framework, the equity value is inferred from a recent financing transaction. It involves making assumptions for the time to liquidity, volatility, and risk-free
rate and then solving for the value of equity such that value for the most recent financing equals the amount paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the PWERM, the
value of a company&#146;s particular equity class is estimated based upon an analysis of future values for the entire enterprise assuming various future outcomes. Share value is based upon the probability-weighted present value of these expected
outcomes, as well as the rights of each class of preferred and common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each grant date, the Board evaluated any recent events
and their potential impact on the estimated fair value per share of the common stock. For grants of stock awards made on dates for which there was no concurrent independent third-party valuation, the Board determined the fair value of the common
stock on the date of grant taking into consideration the immediately preceding valuation report as well as other pertinent information available at the time of the grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>[***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-1003</B></P></TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>May 1, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Page 4 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g637842g74y57.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>VALUATIONS AND OPTION GRANTS OVER THE PREVIOUS
15 MONTHS </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>January&nbsp;31, 2018 Valuation and March&nbsp;31, 2018, April&nbsp;13, 2018, and April&nbsp;30, 2018 Grants </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>January&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO&nbsp;Early</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO&nbsp;Late</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPM</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Probability of Scenario</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Discount for Marketability</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation was performed by Company management and the Board with the assistance of a third-party independent
valuation specialist that determined the fair value of the Company&#146;s common stock as of January&nbsp;31, 2018 to be $[***] per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the hybrid method, the Company computed the probability-weighted value across two scenarios: the IPO and the <FONT
STYLE="white-space:nowrap">non-IPO</FONT> scenarios (estimated using the OPM). The Company assigned a probability of [***]% to the IPO scenarios and the residual probability was assigned to the OPM scenario. As of the valuation date, the Company had
not initiated formal IPO discussions with bankers. However, the Company was preparing to be ready to go public [***] based on the anticipated IND filing of at least one of its programs. If the Company did not complete the IPO by [***], the Company
contemplated another window for IPO financing by [***] when both the programs were expected to enter the clinical development stage. The Company assigned a probability of [***]% to the IPO Early scenario and a probability of [***]% to the IPO Late
scenario. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The equity value for the OPM scenario in the hybrid method was determined by applying the backsolve method such that the
probability-weighted value of the most recent round of financing was equal to its original issue price. The Company considered the backsolve method to be reasonable given the proximity of the Series B convertible preferred stock financing, which had
its initial closing as of the valuation date. Equity values for the IPO scenarios were determined based on the IPO waterfall analysis. In determining the estimated fair value of the Company&#146;s common stock, the Board and the third-party
valuation firm also considered the fact that the Company&#146;s stockholders could not freely trade the common stock in the public markets. Accordingly, the Company applied a Discount for Lack of Marketability (<B><I>&#147;DLOM&#148;</I></B>) to the
Company&#146;s total equity value estimated by the OPM and IPO scenarios. The Company calculated a DLOM of [***]% for the OPM scenario, [***]% for the IPO Early scenario, and [***]% for the IPO Late scenario using the Finnerty and Asian Put Option
analyses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the grants of stock options made on March&nbsp;31, 2018, April&nbsp;13, 2018, and April&nbsp;30, 2018, the
Board concluded that the estimated fair value of the Company&#146;s common stock was $[***] per share in consideration of the valuation analysis as of January&nbsp;31, 2018 and other objective and subjective factors as appropriate. As part of the
determination, the Board concluded that there were no significant value-affecting internal or external developments during such period that warranted a change in the fair value between the January&nbsp;31, 2018 valuation date and the grant dates.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>[***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-1004</B></P></TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>May 1, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Page 5 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g637842g74y57.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>May&nbsp;31, 2018 Valuation and
June&nbsp;20, 2018, June&nbsp;30, 2018, July&nbsp;28, 2018, July&nbsp;31, 2018, August&nbsp;31, 2018, and October&nbsp;3, 2018 Grants </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>May&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO&nbsp;Early</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO&nbsp;Late</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPM</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Probability of Scenario</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Discount for Marketability</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation was performed by Company management and the Board with the assistance of a third-party independent
valuation specialist that determined the fair value of the Company&#146;s common stock as of May&nbsp;31, 2018 to be $[***] per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the hybrid method, the Company computed the probability-weighted value across two scenarios: the IPO and the <FONT
STYLE="white-space:nowrap">non-IPO</FONT> scenarios (estimated using the OPM). The Company assigned a probability of [***]% to the IPO scenarios and the residual probability was assigned to the OPM scenario. As of the valuation date, the Company had
not initiated formal IPO discussions with the bankers. However, the Company was preparing to be ready to go public as early as [***] based on the anticipated IND filing of at least one of its programs. The Company also made key executive hires near
the valuation date, including the addition of each of its Senior Vice President, General Counsel, Head of Operations and Vice President, Head of Biology and Translational Science in May 2018 and its Senior Vice President and Chief Medical Officer,
Head of Development in June 2018. If the Company did not complete the IPO by [***], the Company contemplated another window for IPO financing by [***] when two of its programs were expected to enter the clinical development stage. The Company
assigned a probability of [***]% to the IPO Early scenario and a probability of [***]% to the IPO Late scenario. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Relative to the previous
valuation, the IPO Early and IPO Late scenarios&#146; financings were delayed by three months and six months, respectively, given the Company&#146;s updated timelines to have multiple programs in the clinic or near a Phase 1 start. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The equity value for the OPM scenario in the hybrid method was determined by applying the backsolve method such that the probability-weighted
value of the most recent round of financing was equal to its original issue price. The Company considered the backsolve method to be reasonable given the proximity of the Series B convertible preferred stock financing to the valuation date. Equity
values for the IPO scenarios were determined based on the IPO waterfall analysis. In determining the estimated fair value of the Company&#146;s common stock, the Board and the third-party valuation firm also considered the fact that the
Company&#146;s stockholders could not freely trade the common stock in the public markets. Accordingly, the Company applied a DLOM to the Company&#146;s total equity value estimated by the OPM and IPO scenarios. The Company calculated a DLOM of
[***]% for the OPM scenario, [***]% for the IPO Early scenario, and [***]% for the IPO Late scenario using the Finnerty and Asian Put Option analyses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the grants of stock options made on June&nbsp;20, 2018, June&nbsp;30, 2018, July&nbsp;28, 2018, July&nbsp;31, 2018,
August&nbsp;31, 2018, and October&nbsp;3, 2018, the Board concluded that the estimated fair value of the Company&#146;s common stock was $[***] per share in consideration of the valuation analysis as of May&nbsp;31, 2018 and other objective and
subjective factors as appropriate. As part of the determination, the Board concluded that there were no significant value-affecting internal or external developments during such period that warranted a change in the fair value between the
May&nbsp;31, 2018 date and the grant dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>[***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-1005</B></P></TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>May 1, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Page 6 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g637842g74y57.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>November&nbsp;30, 2018 Valuation
and December&nbsp;11, 2018 and January&nbsp;31, 2019 Grants </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>November&nbsp;30, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO&nbsp;Early</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO&nbsp;Late</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPM</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Probability of Scenario</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Discount for Marketability</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation was performed by Company management and the Board with the assistance of a third-party independent
valuation specialist that determined the fair value of the Company&#146;s common stock as of November&nbsp;30, 2018 to be $[***] per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the hybrid method, the Company computed the probability-weighted value across two scenarios: the IPO and the <FONT
STYLE="white-space:nowrap">non-IPO</FONT> scenarios (estimated using the OPM). The Company assigned a probability of [***]% to the IPO scenarios and the residual probability was assigned to the OPM scenario. As of the valuation date, the Company
considered the following factors in the aggregate in increasing the probabilities for IPO scenarios by [***]%, compared to the previous valuation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company had entered into an exclusive <FONT STYLE="white-space:nowrap">in-license</FONT> agreement with
Novartis in September 2018 to develop and commercialize Novartis&#146; LXS196 (now IDE196), a Phase 1 protein kinase C, or PKC, inhibitor for the treatment of cancers with GNAQ and GNA11 mutations which helped diversify its pipeline with a clinical
stage asset to help support the probability of going public in the near-term. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company nominated a development candidate for its aryl hydrocarbon receptor, or AhR, program in October
2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company had finalized its underwriting syndicate and held an organizational meeting for its IPO in November
2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company hired its Vice President, Head of Regulatory Affairs in November 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the factors above, the Company contemplated another window for an IPO financing by [***] if it was unable to complete an IND
filing for its proprietary program and to account for volatility in the market. The Company assigned a probability of [***]% to the IPO Early scenario and a [***]% to the IPO Late scenario. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The equity value for the OPM scenario in the hybrid method was kept consistent with the previous valuation with an additional consideration of
shares of Series B redeemable convertible preferred stock issued to Novartis in connection with the license agreement. The Company and Novartis effectively valued the Series B redeemable convertible preferred stock at its original issue price as
part of the equity negotiations underlying the license agreement. As a result, the Company did not believe a significant deviation from the Series B redeemable convertible preferred stock original issue price was reasonable for the analysis.
Relative to the previous valuation, the implied Series B redeemable convertible preferred stock value increased modestly given the improved probabilities of an IPO, but the increase was not so significant as to materially deviate from the original
issue price. Equity values for the IPO scenarios were determined based on IPO waterfall analysis. The Company calculated a DLOM of [***]% for the OPM scenario, [***]% for the IPO Early scenario, and [***]% for the IPO Late scenario using the
Finnerty and Asian Put Option analyses. Compared to the previous valuation, the Company applied a lower DLOM considering the compressed term to exit, as well as consideration of restricted stock studies with
<FONT STYLE="white-space:nowrap">1-year</FONT> and <FONT STYLE="white-space:nowrap">2-year</FONT> hold periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the
grants of stock options made on December&nbsp;11, 2018, and January&nbsp;31, 2019, the Board concluded that the estimated fair value of the Company&#146;s common stock was $[***] per share in consideration of the valuation analysis as of
November&nbsp;30, 2018 and other objective and subjective factors as appropriate. As part of the determination, the Board concluded there were no significant value-affecting internal or external developments during such period that warranted a
change in the fair value between the November&nbsp;30, 2018 valuation date and the grant dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>[***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-1006</B></P></TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>May 1, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Page 7 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g637842g74y57.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>February&nbsp;28, 2019 Valuation
and March&nbsp;13, 2019 Grants </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>February&nbsp;28, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO&nbsp;Early</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO&nbsp;Late</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPM</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Probability of Scenario</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Discount for Marketability</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[***]%</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation was performed by Company management and the Board with the assistance of a third-party independent
valuation specialist that determined the fair value of the Company&#146;s common stock as of February&nbsp;28, 2019 to be $[***] per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the hybrid method, the Company computed the probability-weighted value across two scenarios: the IPO and the <FONT
STYLE="white-space:nowrap">non-IPO</FONT> scenarios (estimated using the OPM). The Company assigned a probability of [***]% to the IPO scenarios and the residual probability was assigned to the OPM scenario. As of the valuation date, the Company
considered the following factors in the aggregate in increasing the probabilities for IPO scenarios by [***]%, compared to the previous valuation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company had confidentially submitted the <FONT STYLE="white-space:nowrap">S-1</FONT> to the Commission in
January 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company had completed its &#147;Analyst Day&#148; meeting with equity research analysts in February 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Valuation Date, the Company was in the initial phase of the process of having TTW Meetings, albeit
other steps were still required, such as valuation discussions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the factors above, the Company viewed the
probability of the IPO Early scenario as [***]% as of the Valuation Date. Notwithstanding, if the Company did not go public in the near term, there was another opportunity by the end of the year in the IPO Late scenario. As such, the Company kept
the probability of this scenario at [***]%, which is slightly ([***]%) lower than the previous valuation considering the increase in the probability for the IPO Early scenario. In summary, the probability of the IPO Early scenario increased by 25%,
and the probabilities for aggregate IPO scenarios increased by 20% since the previous valuation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The equity value for the OPM scenario in
the hybrid method was kept consistent with the previous valuation based on the progress made by the Company since the previous valuation. The Company had performed well overall and remained generally on track from a development perspective on all of
its programs. Equity values for the IPO scenarios were determined based on the IPO waterfall analysis. The Company calculated a DLOM of [***]% for the OPM scenario, [***]% for the IPO Early scenario, and [***]% for the IPO Late scenario using the
Finnerty and Asian Put Option analyses. Compared to the previous valuation, the Company applied a lower DLOM considering the compressed term to exit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the grants of stock options made on March&nbsp;13, 2019 and March&nbsp;31, 2019, the Board concluded that the estimated
fair value of the Company&#146;s common stock was $[***] per share in consideration of the valuation analysis as of February&nbsp;28, 2019 and other objective and subjective factors as appropriate. As part of the determination, the Board concluded
there were no significant value-affecting internal or external developments during such period that warranted a change in the fair value between the February&nbsp;28, 2019 valuation date and the grant dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>[***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-1007</B></P></TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>May 1, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Page 8 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g637842g74y57.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>DISCUSSION OF PRELIMINARY IPO PRICE RANGE
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Preliminary IPO Price Range was derived by a quantitative and qualitative analysis that differed from the methodology used by
the Company and its independent valuation specialist. Among the factors that were considered in setting the Preliminary IPO Price Range were the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an analysis of the typical valuation ranges seen in recent IPOs for comparable companies in the Company&#146;s
industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the general condition of the securities markets and the recent market prices of publicly traded common stock of
comparable companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assumption that there would be a receptive public trading market for biotechnology companies such as the
Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assumption that there would be sufficient demand for the Company&#146;s common stock to support an offering of
the size contemplated by the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The midpoint of the Preliminary IPO Price Range of $[***] per share (the
&#147;<B><I>Midpoint Price</I></B>&#148;) exceeds the fair value of the Company&#146;s common stock of $[***] per share as of February&nbsp;28, 2019, which was determined as described above (the
&#147;<B><I>February</I></B><B><I></I></B><B><I>&nbsp;28, 2019 Valuation Price</I></B>&#148;), by $[***] per share. The Company respectfully submits that the difference between the February&nbsp;28, 2019 Valuation Price and the Midpoint Price is
primarily attributable to the fact that the methodology applied for determining the February&nbsp;28, 2019 Valuation Price incorporated multiple probability-weighted liquidity scenarios, not all of which allocate value to the Company&#146;s common
stockholders, and inherently decreases the estimated fair value per share due to the combination of (i)&nbsp;the mix of other expected business equity values discounted for their future value and (ii)&nbsp;the application of a discount to liquidity
event which accounts for lack of marketability. In contrast, the Midpoint Price assumes with 100% probability that the Company completes an IPO and the Company&#146;s preferred stock will be converted into common stock during [***]. Additionally,
the Midpoint Price assumes only a single potential liquidity event, the IPO, and does not include a discount for lack of marketability, as an active trading market for the common stock is expected to exist following the IPO. As a result, the
Midpoint Price was not impacted by other expected business equity values from other potential future liquidity events nor discounted for lack of marketability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s common stock was determined to be $[***] per share as of February&nbsp;28, 2019. In the February&nbsp;28,
2019 valuation report, the discount factor for lack of marketability is applied to the IPO and <FONT STYLE="white-space:nowrap">non-IPO</FONT> scenarios, which accounted for approximately $[***] per share of the approximate $[***] per share
difference between the February&nbsp;28, 2019 Valuation Price and the Midpoint Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company believes that the remaining difference
between the February&nbsp;28, 2019 Valuation Price and the Midpoint Price is attributed to the fact that (i)&nbsp;the Company assumes a successful IPO with no weighting attributed to any other outcome for the Company&#146;s business and
(ii)&nbsp;the valuation report prepared by the Company&#146;s third-party valuation specialist utilized a quantitative methodology to determine the fair value of the Company&#146;s common stock, which may differ from the more qualitative and
subjective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>[***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-1008</B></P></TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>May 1, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Page 9 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g637842g74y57.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">methodology used by some public market investors to
determine the price that they are willing to pay in the IPO, such as the valuations of recently completed public offerings and evaluating those issuers&#146; respective stages of development as compared to the Company, the current valuations of
public companies at a similar stage of clinical development, and recent market conditions. Also, other factors may have an impact, such as the inherent uncertainty of completing an IPO and the possibility that the actual offering price could be
substantially lower than the estimated offering price range determined by the Company and the lead underwriters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CONCLUSION </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the Preliminary IPO Price Range and the other factors described in this letter, the Company respectfully advises the Staff that it
believes that the deemed per share fair values used as the basis for determining stock-based compensation in connection with its stock option grants have been reasonable and appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>[***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-1009</B></P></TD></TR></TABLE>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>May 1, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Page 10 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g637842g74y57.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should the Staff have any questions
or comments regarding the Registration Statement or this letter, please contact me by telephone at (650) <FONT STYLE="white-space:nowrap">463-3043</FONT> or by <FONT STYLE="white-space:nowrap">e-mail</FONT> at mark.roeder@lw.com. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Mark Roeder </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Mark Roeder </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">of LATHAM&nbsp;&amp; WATKINS LLP </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yujiro Hata, IDEAYA Biosciences, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Paul Stone, IDEAYA Biosciences, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mark Roeder, Latham&nbsp;&amp; Watkins LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adam H. Whitaker, Latham&nbsp;&amp; Watkins LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alan F. Denenberg, Davis Polk&nbsp;&amp; Wardwell LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stephen Salmon, Davis Polk&nbsp;&amp; Wardwell LLP </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>[***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by IDEAYA Biosciences, Inc. with respect to portions of this letter. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED BY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDEAYA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>IDYA-10010</B></P></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g637842g31m72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g637842g31m72.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@"JFH6LEXUHLA,RYXV$ D8R V,$C/0&@"&36]/C@28SEHG+X9(V<?*=K'@'
M![]* %;6+%&F#2L/)#%CY38(4X;!QAL$@<9H MP3+<0K*@<*W0.C(?R8 B@"
M2@ H * "@ H * "@ H * .6MO#-Y#<Q.T\)B219=F3P^\$GI_=4#\30 EMX7
MG0A)_*DC\Q&DW.")0I))*B,<G/<MZ9H !X:O%1 XM;E555\B5F"-A6 S\IZ;
MACC\J -272'G33(Y9F86JXD=9&1V.S;D%3GK[T 4[C0)CJMG+;);QVUL4*D_
MZS )+#)4DYSG[P[Y!SF@!+3P[):7-C,H@VP11))'T5V&[<_3[P+ @_7.,YH
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M+(&9BYMSAB1RQ&_[X['H.@'3 !8U'1(]3LQ!/,V^/B*0%@5&!G.&^8G'7WH
M@E\.^8)8Q=!8<NT0\O+*[D$EFS\PR.G!]Z &OX?N',SF^C$MR'2X(@X96QPH
MW?+PN,G/6@#4U&R74;&2U9@JN5SE=PP"#C'X4 9^I^'Q>6\=O9SK96ZJRF..
M,A3D@YPK+Z=#D'/2@">STN:SO;FZ6YC9[D@R#R<#@]L'^Z2.<\\^H(!)=:5'
M=:C;7C2RJ8,_*LK@'\ 0!^7/>@!ZV+1W-U,LJXN64LK)T 7!'7OZT 4H=%G@
MB4+=Q&2%8XX2;?*A4SC<-W)^8\@K[=\@#;?P^UO/&5N@8 Z2.GE?,SJ#@AL\
M#..,'IUH ?=^'H+V[2ZFD<2E"DQC9E#Y7;P-V!^M ##H=PUM)&]W [R[5<-:
MYC957 !7=U[YS^% $]WIM[/:0VT>H*L:8#^9"7,J@ 88[AU.2<8SG'KD KR^
M'VF\Y7NE\N3S'4+%@K(ZX)SGD=2!].>* "70[J7SG:^B$UPLB2L+<X*LJ+P-
MW! 0<DGJ>* -L *  , =!0 M &%_PE=B49EAN&*C.T*,_=9B.O8*<_A0!(OB
M:Q:;RU64@2%&? VK\RKN)ST)<?K0 ^WUV&^L+N>UCD#01;\2KCG!XX/^SS]:
M (;;Q/:RB.-HY?/( *A0!N+A,#)]3GZ4 7;C5H;:YDA>*9DB4-+*BY6,$$C/
M?MV!H J/XD@C3YK*Z$O4Q83<!MW9^]C&,]\\4 7[#4(]0C=DCDCV, 5DQGE0
MP/!/!!% %N@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *"Z+IR3"9
M;90^YVSN/5QAN_?_ /50!&/#VEK$\0M0$>,1-\[<J#D#.?7OUH G32K*-9E2
M'8)W+R!6(W$KM.>>F.W3OUH C70]-6991:@.KK(#N/#*, ]?3_'K0 Y](L9)
M5DDA,C* ,/(S!L9QN!.&QD\G.* &QZ'I\2;5@8]>6D9CRNW&2<]./:@"U;VD
M%J7\E-N_&[DG. %'7V H FH * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M$$>UD$9&T8*C.%^G)X]Z &6MA9V6[[):0V^_&[RHPN<=,X^M  MA9I)+(EI
MKS B1A& 7!ZY/>@"7RH_D_=K^[.4X^[QCCTX)'XT ,EM+:99%EMXG$H <,@.
MX#IGUH BDTK3I88X9+"V>*+.Q&B4A,]<#'% #AIUB)HYA96XEC 5'\I=R@=
M#CB@"S0 4 % !0 4 % !0 4 % !0!Q-GJUQ;O)-$YN95CG+(+QI2,-\I=#P@
M'L: +T.M7%U]F9_*;,FW=%)P1YL(SA'8 _.>"3T]"00!++7+\P(XCB>( ((P
M&+LWD&3[Q8]QCIWH T]$U.34#<AY[:=8F4++;@A6RH)ZD]"<?A0!K4 % !0
M4 % '$6>I7S-:VC3S<72S&0L<M&9 H0GN,EN/]F@"Z/$EV;>1Q)9 @(QS\OE
M$L08VW. 7 'JO0\=,@$C^(K@1-(C6Y81AE@9&$C QA]_!/R@DCIV/S9XH 9+
MXCOHT/E"VN@Q=8I8E;9(4VL2/F/&TN.IY6@#=TNZDO=-ANI5"F4%@%! VDG;
MU]L4 7* "@ H * "@ H * "@ H * "@"O!J%E<S/#;W<$LJ?>1) Q7MR!0 ^
M>WBN0@E!(1Q( &(Y!R,XZ\]C0 YUCGB>-@'C8%6'8]B* (K.QM["-DMU8!CD
MEG9R>,=6)/0"@"Q0 4 % !0 4 0+>6K1JZW,11W\M6#C!;IM'O[4 3T -$B-
M(T:NI=,;E!Y&>F: !)$DW;'5MI*G:<X([4 .H * "@ H * "@ H * "@ H *
M "@#D8M-UE$*Q+/&\:3!3(T6T;FR/+*_,"?5NE $YM-6#PM#'=JBS$I'+<;M
MB$K]]A)D\AC_ !C!QB@!D&FZG;2+'%'<JJR91OM/R+^])9F&[Y@4(XP><\#.
M: -#1K2_M9LW33,KP@OYDV_#[FZ9)Q\N.G% &U0 4 % !0 4 <?:Z'J<4UNC
MPC[-'.MP!O'#[P#W[*"?^!4 68K/69C#%.+J.-/+21OM !?#,6(*MGH5]#0
MQ;/6PBB<74D8504BN0KDA6 (;<.^W///O0!;TS3[^UU'SI/,"R22F4>;N4YV
M[3C@9SGD '^5 &_0 4 % !0 4 % !0 4 % !0 4 % %*VU:SNY_)A=RYW8W1
M.H;!P<$@ X]J +M !0!%-<16_E^:VWS'"+P3ECT% $M !0 4 % !0!4@U.SN
M!&89P_F.T:X!^\N<CVZ'K0!;H BGN8K5%:9MJLP0'!(R3@9].?6@ @N8KGS/
M*;<(W,;'! W#J/?\* ![B*.>*!FQ)*"4&#SCK_.@"6@ H * "@ H * "@ H
M* "@ H Y4>'+XQ2Q[XTS',@/VF1P^\Y VD83'MZ4 6;C0[@W,B00VRV99F5!
M(4/,(CVX"D <9SS]* ((_#]ZGV([;4/;REP05PB[@<!1& 3QU78>?QH 9!X9
MO(9&+.C_ +Q79C+CS<$G)"Q@ACGJ2QYZT :V@Z;-I=G)!*(E4ON18\' P!R0
MJ@GCT_$T :M !0 4 % '-#PW<IY1BN$B8B;S=I/WF5@C#W ;GZ#TH KCPI<M
M L6](5+D.JR C80,X"QH <HO;GUH V;3395T*2SN_*DGF$C2E?NEF)/]?TH
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MCYAT- %ZTU6"\O;BU1662 D-N9.<''0$D?B!F@"]0 4 % !0 4 % !0 4 %
M!0 4 % !0!0_L:P\QW,!.X,-ID8JN[[Q5<X4G)Y !Y/K0 2:-I\C$O;Y)&#\
MS?W0OKZ ?EF@!@T'3@Z.(I-RD-GSG^8ABP+<_,023DYH J67AF&!I3<S&<,
M$VED*88L,'<<'G^':/;F@#9M[>*UMT@A0)&@PHH DH * "@ H K'3[4V+67E
M?Z.V<KN/<Y//7K0!"FC6$<<B"%B)%=7+2,Q8/C=DDYYVCGVH FBL((;I[E1(
M9G!!+RL^ 3D@ DA1[#% %F@ H * "@ H * "@ H * "@ H * "@#FX=1N[:U
MAO9;MK@2M,&@944 ('(*D '^ #G/WJ '7.O7(O8TMX$*H&+H\FT,/+5^NTXQ
MG\: $N/$V&E2.#Y/(DD217.X%4W8.4VY_%L=Q0!T= !0 4 % !0 4 <E;ZKJ
M.XR22W)3RYY#O$01@N0-A SD''WO>@"XGB1CYD0M1YT(^</(>Y4)]U226!S@
M#MQF@!%\07%W#"UO;K&/-B$K%SE0TQCX!49SM/7!&?6@"QH6J7%ZHAND'F>7
MYBR!L[AN8<C P>/>@#:H * "@ H * "@ H * "@ H * "@"M%IUC!(\D-E;Q
MR2 AV2)06!Z@G'- $?\ 8^E^4(O[-M/+!W!?)7 /KC% #SIMBTSS&RMS+("'
M<Q+ELC!R<<\<4 6J "@ H * "@ H @:RM7C6-K:(HI)52@P"<YQ]<G\Z (4T
MFT4W7F1B<7+ NLJJ5PH^50,8P* 'C3+ -$18VX,)S&?*7Y.<\<<<\T 2QVT$
M)!BAC0A=H*J!QG./IF@"6@ H * "@ H * "@ H * "@ H * .2M+X1Q)-:WD
MEQ? SF:%IVD 50Y&5R=O(0<8ZT (?$36\):UGMW@5P,M)YK-^[4D+ND&>21P
M2?8G- $USXCNH)[R)1!(87P"H4B-=^,L?,ZX[-LYH :NN76])GFMX1+%&"[L
M'A3F;GY6QEMBCJ?3G R ,@\07<%K;)OAD<6\9\MPQE?,.XR9S]W/!X['F@#1
MTB6\N=5N)KJ=6 MXML:!E5=V3TW$9]\9^G2@#<H * "@#E(M2%I<W$AO#,ZI
M*S,)F?;@\;X3C9CH,$9[XSP $?B._FM'F3[-^Z$SL3'D.$\O &UR!G>><GH*
M -'6);5-1M$O;UK6 PRG(N6ARP,>.01DX)XH R&U_4;.-0R()&CCW23-@ ["
M<$,ZJ"?;'0\&@"Q-XENXYF"I;$[7/V?EI% CW!L@X*D^@Z"@#9TB]>^AG9Y8
M9A'*46: $)(, Y')[DCJ>E &A0 4 % !0 4 % !0 4 % !0!6AU&QN)V@@O(
M)9ESE$D!88Z\ T 6: &^8@D$6]?,(W!<\X]<?B* &PW$-P&,,R2!6*L48'!'
M4''>@!^X!@N1DC(% "T % !0 4 017MK-<26\5S$\T?WXU<%E^H[4 3T 5[J
M_L[+9]KNX;??G;YL@7..N,_6@"=65U#*05(R"#P10!633;6.^:\6,B9LDG>2
MH) !(7. < <@9H L>8GF^5O7S,;MN><>N* '4 % !0 4 % !0 4 % !0 4 <
M_%IFH0Z))$MQ.)F<XB#(H0&3)(8 '[OJ3UH J3V.M&[N1;K<I"4=%)N2<_,N
MT@F0]@?X5(SCGK0 ]M-U5+Z)U$SV\+2*1Y_[QXRZD .6S[\GMCO0 ME8ZG81
M16Z0SE&:(D^>"(\3,SYRV>5(Z9S0!8TG3;NVU"WN+E9W<VFR1WG+@/NSC!;^
M0Q0!OT % !0 4 <W]DU&(RK;V<@1$EVH\D94%C_RS<8<9Z_-CZCB@""/3M::
MT<2-<K(@F:("Y(.X^7LS\YST?@DCK[4 ;5Y9SW&J6LL4\L"1Q2*SQ["<DI@8
M8'^Z>@[4 9.H6.K-%/\ 9UN&EDG<JPN6 1<?)@!UP.?_ *QXP #6&MD/*DDZ
MSON!S/\ *%\H8PN< [\\XS^% "36>JL&$4=_'#M^1#<AW!W \G>IQC/\><8Y
M[4 /-KK)1ODG6Y,.$=;G]VG[K&"I));?SG![?-Q@@&KI,4\4<_FI-'&9,Q1S
MR^8ZKM&<MN;^+<>I_H #0H * "@ H * "@ H * *T=_;2B$I+D3LR1_*>2N<
M_P C0!9H B>XBCGB@9L22@E!@\XZ_P Z ): "@ H * "@ H J0:G:7%P8(I&
M+\XS&P5L'!VL1AL>Q- %N@"*XN(K6$RS-M0$ G!/4X'3W- $M !0 4 % !0
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M 2Q>'IENVN)M0,I)3 *'@+(KXY8@=,< #VH WJ "@ H * "@ H * "@ H *
M"@#GXO$F5MS*A0%I?.;R7"A4#'Y6/!/RCH3WH M#Q!;JS)+;7$,J*S-&ZKD
M+N[$CD'_ !Q0!!<>)HD2Y6"UD>:%5;:S(,Y*C.-V<?,.P!]: )F\0VZJ[&UN
M=HSL.%_>8<(=OS=F8=<4 :%G=+>6PF6-X_F92CXRI5BI!P2.H/>@">@ H *
M"@# ;6;NW:X-UY<.Q)&$9@<,-IXPQ.V3CDX(Q0!);Z\S$I)"TLQ)"10J 3\\
MHZLV.D?M^.<  ?)XCM8A(S07(C0-AR@ 9E7<5 )R"!Z@#@\T /FU29]*NKJU
MMV6:V8AX90"?EP6'RG&<=.: (9M?6"2XF*J]C$4C5U906<KN/+,!@#;QUR:
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MM214)<'YAU;@?0]: .BM)GN+*"9XS&\D:LR'^$D9Q0!-0 4 % !0 4 % !0
M4 % !0 4 % $"WEJT:NMS$4=_+5@XP6Z;1[^U $] $8N(#$L@FC,;D*K;A@D
MG  /UH BN8+:^!MY3N,95\)(59#V.001WH E@@CMH$@A0)'&-JCT% $E !0
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.. "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g637842g40k53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g637842g40k53.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MF]?+QNW9XQZYH (Y$EC$D3JZ'HRG(- %>34K"&<02WMNDQ.!&TJAORS0!:H
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M$EM<(I3>@!RIYP000: $TW2X=+CD2!Y"LC;B&(QN[D8'&?3IQQ0!RK:'>_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
4H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g637842g74y57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g637842g74y57.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "$ L0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@"GJL\EKH][<0G;)% [H<9P0I(H L6[%[>)V.6903^5 '/R:W=+XF
M6,%?[+$HM&..?.*[NOY"@"7Q#)J5HUO-::B88YIXX/+\E6QN."V30 [5KZYT
M6QTYIKT/NNT2>9D RAR3P.G04 )!KT-]XAMK6QNXYK<PNT@7G# C'/XF@"'7
M-;N['5(EMMOV6U59+SC/RLP4 >AZF@#0\07EQ9:-)+9,!<NR1Q' /S,P']:
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
B4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
